Clinical Trial Update: Dose Range Study of CD5789 in Acne Vulgaris [Phase 2]

View source ↗

Summary

Phase 2 dose range study of CD5789 in acne vulgaris has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acne Vulgaris

Drugs mentioned

• CD5789

Snippet

Sponsor: Galderma R&D | Conditions: Acne Vulgaris | Phase 2 | Status: COMPLETED | Results posted: 2021-09-20